Imagine a tiny, flexible bandage that can be slid through a blood vessel using a thin tube. Instead of using a rigid metal cage to fix a tear in the heart's main artery, this bandage sticks to the leak and slowly dissolves as the body heals itself. It acts like a temporary bridge that lets the artery repair its own walls naturally.
Current aortic dissection treatments are highly invasive, leading to 30% mortality and 60% mid-term complication rates. There is a critical need for a less invasive, mechanically compliant solution that promotes natural tissue repair.
A bioresorbable adhesive patch (AX-GEN01) with radiopaque markers and a custom extrusion machine for producing non-cytotoxic polymeric stitches.
If you are a device manufacturer dealing with the high failure rates of rigid stents — this project developed a bioresorbable adhesive patch that mimics the aorta's mechanical properties. This allows for a less invasive repair that promotes natural tissue regeneration.
If you are a surgical center dealing with 30% mortality rates in current aortic treatments — this project developed a minimally invasive patch that reduces the need for open surgery. This can lead to shorter post-operative stays and higher patient eligibility.
If you are a polymer producer dealing with the need for high-strength, bio-absorbable materials — this project developed a specific electrospun patch and polymeric stitches. These materials are proven to be non-cytotoxic and compatible with the human aorta.
Based on available project data, specific pricing or cost-per-unit information is not provided.
Yes, the project reports that they have scaled-up the manufacturing process of the patch and built an extrusion machine to produce polymeric filaments.
The project mentions a patented microstructure and viscoelasticity, though specific licensing terms are not detailed in the provided text.
The project is focused on clinical trials for commercialization in the EU and USA, including the implementation of a Quality Management System and First in Human Assay.
The project period runs from 2022-05-01 to 2025-01-31, targeting the transition from validation to commercialization.
The project is led by a single Spanish SME, AORTYX SL, with a 100% industry ratio. This lean structure suggests a highly focused, agile development process where the coordinator retains full control over the IP and commercialization strategy without the complexity of academic partnerships.
AORTYX SL, Spain
Contact us to explore licensing opportunities for bioresorbable aortic patches.
